METTL14 and metabolic dysfunction-associated steatotic liver disease: Adipocyte‐specific deletion of Mettl14 increases adipose lipolysis and protects against HFD‐induced obesity, insulin resistance, and nonalcoholic fatty liver disease (NAFLD).